Key result
New real-time PCR assays detect human astroviruses in ~3% of fecal samples, identifying novel strains.
Why the study?
Accurate detection of all known human astrovirus variants by PCR is challenging due to high genetic divergence among HAstV groups.
Does a newly designed real-time PCR assay improve the detection and discrimination of human astroviruses in patient samples?
Observational (n=556)
Does a newly designed real-time PCR assay improve the detection and discrimination of human astroviruses in patient samples?
Newly designed real-time PCR assays successfully detected and differentiated known and novel human astroviruses, identifying novel variants in stool samples for the first time in the Netherlands.
May support astrovirus surveillance in research labs; leaves open clinical diagnostic adoption pending validation studies.
BACKGROUND: Human astroviruses (HAstV) comprise three phylogenetically compact and non-adjacent groups of species including classical HAstV (HAstV-C) and the novel ones (HAstV-VA/HMO and HAstV-MLB). Of these, HAstV-C is known to be responsible for gastroenteritis while the novel HAstV are associated with cases of neurological disorders. Accurate detection of all known variants by (real-time) PCR is challenging because of the high intra- and intergroup genetic divergence of HAstV. OBJECTIVES: To evaluate published HAstV PCR assays in silico, design de novo real-time PCR assays that can detect and discriminate three groups of HAstV, and apply those to patient samples to analyse the prevalence of HAstV in stool and cerebrospinal fluid (CSF) specimens. STUDY DESIGN: In silico evaluation of published PCR assays and design of real-time PCR assays for detection of different subsets of HAstV was conducted within a common computational framework that used all astrovirus full genome sequences from GenBank. The newly designed real-time PCR assays were evaluated in vitro and applied to faecal samples (collected in January-May 2016) and cerebrospinal fluid specimens (2010-2016) from patients in the Netherlands. RESULTS: Quantitative in silico evaluation of published PCRs is provided. The newly designed real-time PCR assays can reliably assign all available HAstV genome sequences to one of the three phylogenetic groups in silico, and differentiate among HAstV-specific controls in vitro. A total of 556 samples were tested using these PCR assays. Fourteen fecal samples (2.5%) tested positive for HAstV, 3 of which could be identified as the novel HAstV-MLB variants. No novel HAstV were found in CSF specimens. CONCLUSION: Newly designed real-time PCR assays with improved detection of all known HAstV allowed the first-time identification of novel astroviruses from stool samples in the Netherlands.
No takes yet. Share an insight, caveat, or question.
Nijhuis et al. (2018) conducted an observational in Human astrovirus infection (n=556). Newly designed real-time PCR assays was evaluated on Detection of human astroviruses in clinical samples. Newly designed real-time PCR assays detected human astroviruses in 2.5% of tested fecal samples, allowing the first-time identification of novel astroviruses in the Netherlands.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: